Effects of financial support on treatment of adolescents with growth hormone deficiency: a retrospective study in Japan
Authors:
- Eri MaedaEMEri Maeda
- Takahiro HigashiTHTakahiro Higashi
- Tomonobu HasegawaTHTomonobu Hasegawa
- Susumu YokoyaSYSusumu Yokoya
- Takahiro MochizukiTMTakahiro Mochizuki
- Tomohiro IshiiTomohiro Ishii
- Junko ItoJIJunko Ito
- Susumu KanzakiSKSusumu Kanzaki
- Akira ShimatsuASAkira Shimatsu
- Koji TakanoKTKoji Takano
- Toshihiro TajimaTTToshihiro Tajima
- Hiroyuki TanakaHTHiroyuki Tanaka
Open Access
- 21 October 2016
- journal article
- research article
- Published by Springer Nature in BMC Health Services Research
- Vol. 16 (1) , 602
Abstract
Treatment costs for children with growth hormone (GH) deficiency are subsidized by the government in Japan if the children meet clinical criteria, including height limits (boys: 156.4 cm; girls: 145.4 cm). However, several funding programs, such as a subsidy provided by local governments, can be used by those who exceed the height limits. In this study, we explored the impacts of financial support on GH treatment using this natural allocation. A retrospective analysis of 696 adolescent patients (451 boys and 245 girls) who reached the height limits was conducted. Associations between financial support and continuing treatment were assessed using multiple logistic regression analyses adjusting for age, sex, height, growth velocity, bone age, and adverse effects. Of the 696 children in the analysis, 108 (15.5 %) were still eligible for financial support. The proportion of children who continued GH treatment was higher among those who were eligible for support than among those who were not (75.9 % vs. 52.0 %, P < 0.001). The odds ratios of financial support to continuing treatment were 4.04 (95 % confidence interval [CI]: 1.86–8.78) in boys and 1.72 (95 % CI: 0.80–3.70) in girls, after adjusting for demographic characteristics and clinical factors. Financial support affected decisions on treatment continuation for children with GH deficiency. Geographic variations in eligibility for financial support pose an ethical problem that needs policy attention. An appropriate balance between public spending on continuation of therapy and improved quality of life derived from it should be explored.Keywords
Funding Information
- Japan Society for the Promotion of Science (26-1591)
This publication has 38 references indexed in Scilit:
- Low bone status in Indian growth hormone-deficient childrenJournal of Pediatric Endocrinology and Metabolism, 2012
- Medical aid program for chronic pediatric diseases of specified categories in Japan: Current status and future prospectsPediatrics International, 2008
- Effects of insurance status on children's access to specialty care: a systematic review of the literatureBMC Health Services Research, 2007
- Short Stature and the Risk of Adiposity, Insulin Resistance, and Type 2 Diabetes in Middle AgeDiabetes Care, 2006
- Growing up with idiopathic short stature: psychosocial development and hormone treatment; a critical reviewArchives of Disease in Childhood, 2006
- Improved Asthma Care After Enrollment in the State Children's Health Insurance Program in New YorkPediatrics, 2006
- Effects of the State Children's Health Insurance Program Expansions on Children With Chronic Health ConditionsPediatrics, 2005
- Height and Social Adjustment: Are Extremes a Cause for Concern and Action?Pediatrics, 2004
- hGH for short stature: ethical issues raised by expanded accessThe Journal of Pediatrics, 2004
- Women's height, reproductive success and the evolution of sexual dimorphism in modern humansProceedings Of The Royal Society B-Biological Sciences, 2002